Deceleration of Disease Progress Through Ayurvedic Treatment in Nondialysis Stages IV–V Patients with Chronic Renal Failure: A Quasi-Experimental Clinical Pilot Study with One Group Pre- and Postdesign and Two Premeasurements
- 1 May 2020
- journal article
- research article
- Published by Mary Ann Liebert Inc in The Journal of Alternative and Complementary Medicine
- Vol. 26 (5), 384-391
- https://doi.org/10.1089/acm.2019.0419
Abstract
Objective: The aim of this study was to evaluate the effects of Ayurvedic treatment on deceleration of the disease progress of nondialysis patients with stage IV or V chronic renal failure (CRF). Materials and Methods: A complex oral and proctocolonic Ayurvedic multiherbal medication was administered daily for 1 month to inpatients. Thereafter, patients were treated as outpatients with oral medication for additional 5 months. Four renal function tests (RFTs) were evaluated at various time points (TPs): (1) 6 months before baseline (TP −6), (2) at baseline (TP 0), and (3) after completion of 6 months of treatment (TP +6). Repeated-measures analysis of variance (ANOVA) with Greenhouse–Geisser correction and Friedman's ANOVA by ranks were used to analyze the RFTs. For post hoc tests, the Bonferroni correction was applied. Bias-corrected effect sizes (Hedges) for the treatment were calculated. Results: Sixty-four nondialysis CRF patients with laboratory investigations of the preceding 6 months were included; 12 patients discontinued the treatment. Fifty-two patients with stage IV or V at baseline completed the study. Mean concentrations of estimated glomerular filtration rate (eGFR), serum creatinine, and hemoglobin differed significantly between TPs (eGFR: F = 15.3, p < 0.001; serum creatinine: F = 29.3, p < 0.001; blood urea: F = 2.0, p = 0.159; hemoglobin: F = 53.9, p < 0.001). Pairwise comparisons of the mean differences between TPs are significant for eGFR, creatinine, and hemoglobin. For blood urea, a significant decrease was observed for the treatment period [15.9(↓) mg/dL, standard error 4.0; n = 52], but a nonsignificant increase was observed for the pretreatment period [16.2(↑) mg/dL, standard error 9.8] due to insufficient data for TP −6 (n = 26). The effect sizes for eGFR, creatinine, blood urea, and hemoglobin were medium (0.45, 0.53, 0.44, and 0.30). Conclusions: After 6 months of treatment, statistically and clinically significant improvements of eGFR, creatinine, blood urea, and hemoglobin and a significant shift to better CRF stages were observed. Several cardinal symptoms were also significantly reduced. Randomized controlled trials are warranted to evaluate the effects in comparison to usual care.Keywords
This publication has 11 references indexed in Scilit:
- Current status of end-stage renal disease care in India and PakistanKidney International Supplements, 2013
- Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2012
- Incidence of ESRD in IndiaKidney International, 2011
- Effects of Ayurvedic treatment on 100 patients of chronic renal failure (other than diabetic nephropathy)Ayu, 2011
- Effect of Ayurvedic management in 130 patients of diabetic nephropathyAyu, 2011
- Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2007
- The burden of chronic kidney diseaseBMJ, 2006
- Incidence of chronic kidney disease in IndiaNephrology Dialysis Transplantation, 2005
- End-stage renal disease in India and Pakistan: Burden of disease and management issuesKidney International, 2003
- Slowing the progression of chronic renal failure: Economic benefits and patients' perspectivesAmerican Journal of Kidney Diseases, 2002